Intestinal growth in parenterally-fed rats induced by the combined effects of glucagon-like peptide 2 and epidermal growth factor

Journal of Parenteral and Enteral Nutrition

Volumn 29, Issue 4, 2005, Pages 248-254

  Kitchen, Paul A ^a,b   Goodlad, Robert A ^c   FitzGerald, Anthony J ^b,c   Mandir, Nikki ^c   Ghatei, Mohammed A ^b   Bloom, Stephen R ^b   Berlanga Acosta, Jorge ^d   Playford, Raymond J ^b   Forbes, Alastair ^a   Walters, Julian R F ^b  

^a ST MARK S HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^d CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; GLUCAGON LIKE PEPTIDE 2; RNA; GLUCAGON LIKE PEPTIDE; PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION; HISTOLOGY; INTESTINE CELL; INTESTINE FUNCTION; NONHUMAN; NORTHERN BLOTTING; PARENTERAL NUTRITION; PRIORITY JOURNAL; RAT; SHORT BOWEL SYNDROME; ADAPTATION; ANIMAL; CELL DIVISION; DISEASE MODEL; DRUG EFFECT; DRUG POTENTIATION; GROWTH, DEVELOPMENT AND AGING; MALE; ORGAN SIZE; PATHOLOGY; RANDOMIZATION; SMALL INTESTINE; WISTAR RAT;

ADAPTATION, PHYSIOLOGICAL; ANIMALS; CELL DIVISION; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; EPIDERMAL GROWTH FACTOR; GLUCAGON-LIKE PEPTIDE 2; GLUCAGON-LIKE PEPTIDES; INTESTINE, SMALL; MALE; ORGAN SIZE; PARENTERAL NUTRITION; PEPTIDES; RANDOM ALLOCATION; RATS; RATS, WISTAR; SHORT BOWEL SYNDROME;

EID: 27744466840     PISSN: 01486071     EISSN: None     Source Type: Journal    
DOI: 10.1177/0148607105029004248     Document Type: Article

References (35)

1. Nightingale J, ed. Intestinal Failure. London: Greenwich Medical Media; 2001.
2. Wright NA, Goodlad RA. Cytokines and growth factors in gastroenterology. Ballieres Clin Gastroenterol. 1996;10:1.
3. Goodlad RA, Wilson TJ, Lenton W, Gregory H, McCullagh KG, Wright NA. Intravenous but not intragastric urogastrone-EGF is trophic to the intestine of parenterally fed rats. Gut. 1987;28:573-582.
4. Sullivan PB, Brueton MJ, Tabara Z, Goodlad RA, Lee CY, Wright NA. Epidermal growth factor in necrotising enteritis. Lancet. 1991;338:53-54.
5. Walker-Smith JA, Phillips AD, Walford N, et al. Intravenous epidermal growth factor/urogastrone increases small-intestinal cell proliferation in congenital microvillous atrophy. Lancet. 1985;2:1239-1240.
6. Berlanga-Acosta J, Playford RJ, Mandir N, Goodlad RA. Gastrointestinal cell proliferation and crypt fission are separate but complementary means of increasing tissue mass following infusion of epidermal growth factor in rats. Gut. 2001;48:803-807.
7. Heitz P, Kasper M, Van Norden S, Polak JM, Gregory H, Pearse AGE. Immunohistochemistry localisation of urogastrone to human duodenal and submaxillary glands. Gut. 1978;19:408-413.
8. Playford RJ, Hanby AM, Gschmeissner S, Peiffer LP, Wright NA, McGarrity T. The epidermal growth factor receptor (EGF-R) is present on the basolateral, but not the apical, surface of enterocytes in the human gastrointestinal tract. Gut. 1996;39:262-266.
9. Drucker DJ. Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology. 2002;122:531-544.
10. Bell GI, Sanchez-Pescador R, Laybourn PJ, Najarian RC. Exon duplication and divergence in the human preproglucagon gene. Nature. 1983;304:368-371.
11. Mojsov S, Henrich G, Wilson IB, Ravazzola M, Orci L, Habener JF. Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing. J Biol Chem. 1986;261:11880-11889.
12. Orskov C, Holst JJ. Radio-immunoassays for glucagon-like peptides 1 and 2 (GLP-1 and GLP-2). Scand J Clin Lab Invest. 1987;47:165-174.
13. Orskov C, Holst JJ, Knuhtsen S, Baldissera FG, Poulsen SS, Nielsen OV. Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas. Endocrinology. 1986;119:1467-1475.
14. Dhanvantari S, Seidah NG, Brubaker PL. Role of prohormone convertases in the tissue-specific processing of proglucagon. Molec Endo. 1996;10:342-355.
15. Munroe DG, Gupta AK, Kooshesh F, et al. Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2. Proc Natl Acad Sci USA. 1999;96:1569-1573.
16. Yusta B, Huang L, Munroe D, et al. Enteroendocrine localization of GLP-2 receptor expression in humans and rodents. Gastroenterology. 2000;119:744-755.
17. Bjerknes M, Cheng H. Modulation of specific intestinal epithelial progenitors by enteric neurons. Proc Natl Acad Sci USA. 2001;98:12497-12502.
18. Walsh NA, Yusta B, Dacambra MP, Anini Y, Drucker DJ, Brubaker PL. Glucagon-like peptide-2 receptor activation in the rat intestinal mucosa. Endocrinology. 2003;144:4385-4392.
19. Swietlicki E, Iordanov H, Fritsch C, Yi L, Levin MS, Rubin DC. Growth factor regulation of PC4/TIS7, an immediate early gene expressed during gut adaptation after resection. JPEN J Parenter Enteral Nutr. 2003;27:123-131.
20. Jeppesen PB, Hartmann B, Thulesen J, et al. Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. Gastroenterology. 2001;120:806-815.
21. Drucker DJ, Ehrlich P, Asa SL, Brubaker PL. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci USA. 1996;93:7911-7916.
22. Chance WT, Foley-Nelson T, Thomas I, Balasubramaniam A. Prevention of parenteral nutrition-induced gut hypoplasia by coinfusion of glucagon-like peptide-2. Am J Physiol. 1997;273: G559-G563.
23. Kitchen PA, Fitzgerald AJ, Goodlad RA, et al. Glucagon-like peptide-2 increases sucrase-isomaltase but not caudal-related homeobox protein-2 gene expression. Am J Physiol. 2000;278: G425-G428.
24. Ghatei MA, Goodlad RA, Taheri S, et al. Proglucagon-derived peptides in intestinal epithelial proliferation-glucagon-like peptide-2 is a major mediator of intestinal epithelial proliferation in rats. Dig Dis Sci. 2001;46:1255-1263.
25. Martin GR, Wallace LE, Sigalet DL. Glucagon-like peptide-2 induces intestinal adaptation in parenterally fed rats with short bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2004;286:G964-G972.
26. Drucker DJ, Deforest L, Brubaker PL. Intestinal response to growth factors administered alone or in combination with human [Gly(2)]glucagon-like peptide 2. Am J Physiol Gastrointest Liver Physiol. 1997;36:G1252-G1262.
27. Howard A, Goodlad RA, Walters JR, Ford D, Hirst BH. Increased expression of specific intestinal amino acid and peptide transporter mRNA in rats fed by PN is reversed by GLP-2. J Nutr. 2004;134:2957-2964.
28. Barley NF, Taylor V, Shaw-Smith CJ, et al. Human ileal bile acid-binding protein promoter and the effects of CDX2. Biochim Biophys Acta. 2003;1630:138-143.
29. Playford RJ, Marchbank T, Mandir N, et al. Effects of keratinocyte growth factor (KGF) on gut growth and repair. J Pathol. 1998;184:316-322.
30. Barley NF, Prathalingam SR, Zhi P, Legon S, Howard A, Walters JRF. Factors involved in the duodenal expression of the human calbindin-D9k gene. Biochem J. 1999;341:491-500.
31. Barley NF, Chakravarty P, Sitrin MD, et al. Gene expression in transposed segments of rat small intestine. Gastroenterology. 1997;112:A860.
32. Playford RJ, Wassan H, Ghosh S. Effects of growth factors and receptor blockade on gastrointestinal cancer. Gut. 2004;53:1059-1063.
33. Goodlad RA, Mandir N, Meeran K, Ghatei MA, Bloom SR, Playford RJ. Does the response of the intestinal epithelium to keratinocyte growth factor vary according to the method of administration? Regul Pept. 2000;87:83-90.
34. Bashir O, Fitzgerald AJ, Berlanga-Acosta J, Playford RJ, Goodlad RA. Effect of EGF administration on intestinal cell proliferation, crypt fission and polyp formation in Min mice. Clin Sci. 2003;105:323-330.
35. Thulesen J, Hartmann B, Hare KJ, et al. Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice. Gut. 2004;53:1145-1150.